Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Research Report 2024

Publication ID:

PB510246666

Publication Date:

October 16, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.
The global Peptide-Drug Conjugates(PDCs) CDMO Service market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Peptide-Drug Conjugates(PDCs) CDMO Service is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Peptide-Drug Conjugates(PDCs) CDMO Service is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Peptide-Drug Conjugates(PDCs) CDMO Service in SME Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Peptide-Drug Conjugates(PDCs) CDMO Service include WUXIAPP, Medicilon, Creative Peptides, Peptistar, BOCSCI Inc, HUATENG PHARMA, CPC Scientific Inc, Porton, VIVA Biotech, Taichu Group, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Peptide-Drug Conjugates(PDCs) CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-Drug Conjugates(PDCs) CDMO Service.
The Peptide-Drug Conjugates(PDCs) CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide-Drug Conjugates(PDCs) CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-Drug Conjugates(PDCs) CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
WUXIAPP
Medicilon
Creative Peptides
Peptistar
BOCSCI Inc
HUATENG PHARMA
CPC Scientific Inc
Porton
VIVA Biotech
Taichu Group
PharosGen
CENTER LABORATORIES, INC
JIUZHOU Pharmaceutical
Segment by Type
Therapeutic
Diagnostic
Segment by Application
SME Pharmaceutical Company
Large Pharmaceutical Company
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-Drug Conjugates(PDCs) CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Therapeutic
1.2.3 Diagnostic
1.3 麻豆原创 by Application
1.3.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Perspective (2019-2030)
2.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Growth Trends by Region
2.2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Peptide-Drug Conjugates(PDCs) CDMO Service Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Peptide-Drug Conjugates(PDCs) CDMO Service Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Dynamics
2.3.1 Peptide-Drug Conjugates(PDCs) CDMO Service Industry Trends
2.3.2 Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Drivers
2.3.3 Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Challenges
2.3.4 Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-Drug Conjugates(PDCs) CDMO Service Players by Revenue
3.1.1 Global Top Peptide-Drug Conjugates(PDCs) CDMO Service Players by Revenue (2019-2024)
3.1.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide-Drug Conjugates(PDCs) CDMO Service Revenue
3.4 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Concentration Ratio
3.4.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-Drug Conjugates(PDCs) CDMO Service Revenue in 2023
3.5 Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service Head office and Area Served
3.6 Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service, Product and Application
3.7 Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-Drug Conjugates(PDCs) CDMO Service Breakdown Data by Type
4.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecasted 麻豆原创 Size by Type (2025-2030)
5 Peptide-Drug Conjugates(PDCs) CDMO Service Breakdown Data by Application
5.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size (2019-2030)
6.2 North America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2019-2024)
6.4 North America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size (2019-2030)
7.2 Europe Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2019-2024)
7.4 Europe Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size (2019-2030)
9.2 Latin America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 WUXIAPP
11.1.1 WUXIAPP Company Details
11.1.2 WUXIAPP Business Overview
11.1.3 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.1.4 WUXIAPP Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.1.5 WUXIAPP Recent Development
11.2 Medicilon
11.2.1 Medicilon Company Details
11.2.2 Medicilon Business Overview
11.2.3 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.2.4 Medicilon Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.2.5 Medicilon Recent Development
11.3 Creative Peptides
11.3.1 Creative Peptides Company Details
11.3.2 Creative Peptides Business Overview
11.3.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.3.4 Creative Peptides Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.3.5 Creative Peptides Recent Development
11.4 Peptistar
11.4.1 Peptistar Company Details
11.4.2 Peptistar Business Overview
11.4.3 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.4.4 Peptistar Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.4.5 Peptistar Recent Development
11.5 BOCSCI Inc
11.5.1 BOCSCI Inc Company Details
11.5.2 BOCSCI Inc Business Overview
11.5.3 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.5.4 BOCSCI Inc Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.5.5 BOCSCI Inc Recent Development
11.6 HUATENG PHARMA
11.6.1 HUATENG PHARMA Company Details
11.6.2 HUATENG PHARMA Business Overview
11.6.3 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.6.4 HUATENG PHARMA Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.6.5 HUATENG PHARMA Recent Development
11.7 CPC Scientific Inc
11.7.1 CPC Scientific Inc Company Details
11.7.2 CPC Scientific Inc Business Overview
11.7.3 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.7.4 CPC Scientific Inc Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.7.5 CPC Scientific Inc Recent Development
11.8 Porton
11.8.1 Porton Company Details
11.8.2 Porton Business Overview
11.8.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.8.4 Porton Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.8.5 Porton Recent Development
11.9 VIVA Biotech
11.9.1 VIVA Biotech Company Details
11.9.2 VIVA Biotech Business Overview
11.9.3 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.9.4 VIVA Biotech Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.9.5 VIVA Biotech Recent Development
11.10 Taichu Group
11.10.1 Taichu Group Company Details
11.10.2 Taichu Group Business Overview
11.10.3 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.10.4 Taichu Group Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.10.5 Taichu Group Recent Development
11.11 PharosGen
11.11.1 PharosGen Company Details
11.11.2 PharosGen Business Overview
11.11.3 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.11.4 PharosGen Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.11.5 PharosGen Recent Development
11.12 CENTER LABORATORIES, INC
11.12.1 CENTER LABORATORIES, INC Company Details
11.12.2 CENTER LABORATORIES, INC Business Overview
11.12.3 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.12.4 CENTER LABORATORIES, INC Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.12.5 CENTER LABORATORIES, INC Recent Development
11.13 JIUZHOU Pharmaceutical
11.13.1 JIUZHOU Pharmaceutical Company Details
11.13.2 JIUZHOU Pharmaceutical Business Overview
11.13.3 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
11.13.4 JIUZHOU Pharmaceutical Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service Business (2019-2024)
11.13.5 JIUZHOU Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

WUXIAPP
Medicilon
Creative Peptides
Peptistar
BOCSCI Inc
HUATENG PHARMA
CPC Scientific Inc
Porton
VIVA Biotech
Taichu Group
PharosGen
CENTER LABORATORIES, INC
JIUZHOU Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.